LOCUS BIOSCIENCES INC
MORRISVILLE, NORTH CAROLINA 275607166
Contract Awards
6 awards found
ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1. ADD $14,773,583.00 OF SUPPLEMENTAL FUNDING TO CLIN 0002. 2. ADD $3,226,417.00 OF SUPPLEMENTAL FUNDING TO CLIN 0003.
THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1.SUPPLEMENTALLY FUND CLIN 0003. 2.UPDATE KEY PERSONNEL. 3.EXTEND PERIOD OF PERFORMANCE FOR CLINS 0002 AND 0003 TO END 12/31/2026.
THE PURPOSES OF THIS MODIFICATION ARE TO 1. EXERCISE OPTION PERIOD 1 CLIN 0002 WITH A PERIOD OF PERFORMANCE OF JANUARY 19, 2024 TO SEPTEMBER 30, 2025. 2. INCREASE THE INDIRECT RATE CAPS AS A RESULT OF THIS MODIFICATION: 1. FUNDING IN THE AM
THE PURPOSES OF THIS BILATERAL MODIFICATION ARE TO: 1) ADD $7,809,935.00 UNDER THE BASE PERIOD CLIN 0001 WITH A PERIOD OF PERFORMANCE OF SEPTEMBER 28, 2022 ? MARCH 31 2023; 2) EXTEND THE PERIOD OF PERFORMANCE TO SEPTEMBER 20, 2024; 3) AND UPDATE
ADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY E. COLI.
Business Details
- UEI
- CJKVLKZGX6F3
- CAGE Code
- 7H2T2
- Address
- 523 DAVIS DR STE 350
STE 350
MORRISVILLE, NC 275607166 - Congressional District
- NC-04
- Phone
- 9193139648
Parent Company
LOCUS BIOSCIENCES INC
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov